Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com -- please visit the site to read the full articles, in addition to many other free tools and strategies related to binary event investing.

Nephros (OTCBB:NEPH) Receives 510(k) Response from the FDA

Posted: Thu, 08 Jul 2010 09:30:43 +0000

Within a time span of a few months in 2009, NEPH went from $.04 to $2.63 and fueled the biotech fire. However all of Nephros' applications to the FDA were 510K (medical devices), and thus given no catalyst date.  Take a look at the chart for NEPH: Time has dragged on, and over a year [...]

Transparency in Trading

Posted: Wed, 07 Jul 2010 09:30:42 +0000

In 2009 the markets were roaring back after a steep decline.  You could practically throw a dart at a dartboard full of stock tickers, and pick a winner.  Times have changed. The market has slowed, if not reversed, and it is much more difficult to pick winners, or even to pick methods that are consistently effective.  I [...]

Another Great Resource - The Office of the Federal Register

Posted: Tue, 06 Jul 2010 09:30:56 +0000

Published every Federal working day, the Federal Register is the official gazette of the United States Government. It provides legal notice of administrative rules and notices and Presidential documents in a comprehensive, uniform manner. Documents are on file at the Office of the Federal Register (OFR) and will be published in the Federal Register on [...]

This Week's Watchlist 7/5/10

Posted: Mon, 05 Jul 2010 05:55:35 +0000

Note: The US stock market is closed on Monday in observance of the 4th of July holiday. Vivus (NASDAQ:VVUS) remains on the weekly watchlist as activity and interest in the company should pick up this week and into next week's FDA Panel on 7/15.  For those playing the run-up, remember that the FDA releases [...]

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials.

The actively managed HavRx Regulatory Catalyst Index update report is currently tracking 594 entries and 397 companies (including approximately 200 stocks trading under $5 per share and 57 private companies). Subscribers also have access to my real money portfolio tracker, Google Calendar event tracking for over 1,000 stocks in the HavRx Indexes, and real-time trading / article updates on the member forum. Click on the following email archive web link for a 50% discount promo code... http://eepurl.com/FWdn

Disclosure: No positions